EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.
BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...
Zacks.com on MSN7d
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin UpCTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...
Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback